Breedlove Mark H.
Known title: DirectorCIK: 0001876529
Associated companies
Transaction History
| CGTX | ▼ Sell | Other | 44,806 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 36,714 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 225,281 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 93,296 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 4,354 | $139 | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Open Market | 12 | $141 | 10/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20
Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20. Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.